Onconova Therapeutics (ONTX) Raised to “Hold” at ValuEngine

Onconova Therapeutics (NASDAQ:ONTX) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Several other research analysts also recently commented on ONTX. Zacks Investment Research downgraded shares of Onconova Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. HC Wainwright set a $6.00 price target on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Finally, Maxim Group downgraded shares of Onconova Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $8.00.

Onconova Therapeutics (ONTX) traded down $0.04 during mid-day trading on Wednesday, reaching $0.99. 181,279 shares of the company traded hands, compared to its average volume of 482,010. The stock has a market cap of $19.27, a P/E ratio of -0.35 and a beta of 0.22. Onconova Therapeutics has a 52 week low of $0.95 and a 52 week high of $3.88.

Onconova Therapeutics (NASDAQ:ONTX) last posted its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.10. The company had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.31 million. Onconova Therapeutics had a negative net margin of 3,061.37% and a negative return on equity of 558.97%. analysts expect that Onconova Therapeutics will post -1.66 EPS for the current year.

In other Onconova Therapeutics news, major shareholder 683 Capital Management, Llc bought 200,000 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were acquired at an average price of $1.04 per share, with a total value of $208,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 13.30% of the company’s stock.

A hedge fund recently raised its stake in Onconova Therapeutics stock. 683 Capital Management LLC raised its holdings in shares of Onconova Therapeutics Inc (NASDAQ:ONTX) by 24.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 464,934 shares of the biopharmaceutical company’s stock after purchasing an additional 89,934 shares during the period. 683 Capital Management LLC owned 4.32% of Onconova Therapeutics worth $697,000 at the end of the most recent reporting period. 12.72% of the stock is owned by institutional investors.

WARNING: “Onconova Therapeutics (ONTX) Raised to “Hold” at ValuEngine” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2018/03/14/onconova-therapeutics-ontx-raised-to-hold-at-valuengine.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply